UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3

Annals of oncology, 2018-10, Vol.29, p.viii90-viii90

2018

Volltextzugriff (PDF)

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

Annals of oncology, 2018-10, Vol.29, p.viii91-viii91

2018

Volltextzugriff (PDF)

Repair of a Large Full-Thickness Lower Lip Defect

Dermatologic surgery, 2022-12, Vol.48 (12), p.1333-1335

2022

Volltextzugriff (PDF)

Long-term safety of left renal vein division and ligation to expedite complex abdominal aortic surgery

Journal of vascular surgery, 2009-09, Vol.50 (3), p.500-504

2009

Volltextzugriff (PDF)

PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

Value in health, 2020-05, Vol.23, p.S45-S45

2020

Volltextzugriff (PDF)

PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

Value in health, 2020-05, Vol.23, p.S39-S39

2020

Volltextzugriff (PDF)

PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2– Advanced Breast Cancer (ABC) in Brazil

Value in health, 2021-06, Vol.24, p.S27-S27

2021

Volltextzugriff (PDF)

PCN98 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2− Advanced Breast Cancer (ABC) in the US

Value in health, 2021-06, Vol.24, p.S37-S37

2021

Volltextzugriff (PDF)

330P Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2− advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)

Annals of oncology, 2020-09, Vol.31, p.S377-S378

2020

Volltextzugriff (PDF)

PALBOCICLIB DOSING, WASTAGE AND COSTS AMONG POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) METASTATIC BREAST CANCER (MBC): A CLAIMS ANALYSIS

Value in health, 2017-05, Vol.20 (5), p.A105

2017

Volltextzugriff (PDF)

276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC)

Annals of oncology, 2020-09, Vol.31, p.S350-S351

2020

Volltextzugriff (PDF)

142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial

Annals of oncology, 2020-05, Vol.31, p.S66-S66

2020

Volltextzugriff (PDF)

144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)

Annals of oncology, 2020-05, Vol.31, p.S67-S68

2020

Volltextzugriff (PDF)

291ORibociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

290OPatient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

308PDUpdated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-14

2019

Volltextzugriff (PDF)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer

Cancer management and research, 2021-01, Vol.13, p.8179-8189

2021

Volltextzugriff (PDF)

An operator method for evaluating Laplace transforms

International journal of mathematical education in science and technology, 2005-07, Vol.36 (5), p.553-559

2005

Volltextzugriff (PDF)

Okadaic acid production from the marine dinoflagellate Prorocentrum belizeanum Faust isolated from the Belizean coral reef ecosystem

Toxicon (Oxford), 1998, Vol.36 (1), p.201-206

1998

Volltextzugriff (PDF)

The role of big business in the economic integration of latin america

International journal of organization theory and behavior, 2001-03, Vol.4 (1/2), p.57-73

Lanoue, Darryl B

2001

Volltextzugriff (PDF)

A historical analysis of the international business perspectives of Mexican industrial groups

Journal of management history, 1999-08, Vol.5 (5), p.252-268

Lanoue, Darryl B

1999

Volltextzugriff (PDF)

Active analog power filters provide solutions for EMC and EMI

Nineteenth Annual IEEE Applied Power Electronics Conference and Exposition, 2004. APEC '04, 2004, Vol.2, p.675-680 vol.2

2004

Volltextzugriff (PDF)

Abstracts of the 20th International Isotope Society (UK group) Symposium: Synthesis & Applications of Labelled Compounds 2011

Journal of labelled compounds & radiopharmaceuticals, 2012-03, Vol.55 (3), p.125-134

2012

Volltextzugriff (PDF)

Genetic analysis of vein function in the Drosophila embryonic nervous system

Genome, 2000-06, Vol.43 (3), p.564-573

2000

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Englisch
(122)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(56)
Animals
(37)
Biological And Medical Sciences
(32)
Male
(25)
Rats
(22)
Female
(21)
Fundamental And Applied Biological Sciences. Psychology
(21)
Humans
(20)
Biochemistry & Molecular Biology
(16)
Medical Sciences
(12)
Mice
(9)
Middle Aged
(8)
Rats, Sprague-Dawley
(8)
Social Sciences
(8)
Calcium - Metabolism
(7)
Genetics & Heredity
(7)
Kinetics
(7)
Pregnancy
(7)
Adult
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

Repair of a Large Full-Thickness Lower Lip Defect

Long-term safety of left renal vein division and ligation to expedite complex abdominal aortic surgery

PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2– Advanced Breast Cancer (ABC) in Brazil

PCN98 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2− Advanced Breast Cancer (ABC) in the US

330P Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2− advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)

PALBOCICLIB DOSING, WASTAGE AND COSTS AMONG POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) METASTATIC BREAST CANCER (MBC): A CLAIMS ANALYSIS

276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC)

142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial

144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)

291ORibociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

290OPatient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3

308PDUpdated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial

Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer

An operator method for evaluating Laplace transforms

Okadaic acid production from the marine dinoflagellate Prorocentrum belizeanum Faust isolated from the Belizean coral reef ecosystem

The role of big business in the economic integration of latin america

A historical analysis of the international business perspectives of Mexican industrial groups

Active analog power filters provide solutions for EMC and EMI

Abstracts of the 20th International Isotope Society (UK group) Symposium: Synthesis & Applications of Labelled Compounds 2011

Genetic analysis of vein function in the Drosophila embryonic nervous system

Suchergebnisse filtern